Drug details

Erivedge (vismodegib)

type of Antineoplastics Hedgehog Pathway Inhibitors

Erivedge (vismodegib) is an inhibitor of the hedgehog (Hh) signaling pathway indicated for the treatment of adults with certain forms of skin cancer, including metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat, and
• missed menstrual period

The following drugs are related to Erivedge, either as a replacement or used together:

• Aldara (imiquimod)
• Sancuso (granisetron transdermal system)
• Udenyca (pegfilgrastim-cbqv injection)